With over 3 600 Western Cape users, lenacapavir is “cool”
From counselling about small nodules to overcoming people’s fears of needles, Biénne Huisman takes the pulse of a new HIV prevention injection’s rollout in the Western Cape.
From counselling about small nodules to overcoming people’s fears of needles, Biénne Huisman takes the pulse of a new HIV prevention injection’s rollout in the Western Cape.
A cutting-edge, South African-led HIV vaccine trial built on decades of research recently kicked off in Cape Town. Elri Voigt unpacks what exactly is being studied, and how the resilience, tenacity and urgency of a group of dedicated South African researchers made it possible.
A dire picture for HIV/Aids funding emerged at the 12th South African AIDS Conference, raising the call for resilience, adapting and also for government to raise its game, reports Ufrieda Ho.
The obesity epidemic will hit South Africa hard on top of our high HIV burden, but advocate researcher and scientist Dr Nomathemba Chandiwana says she is ready to fight back harder. She speaks to Ufrieda Ho about her journey from working in state hospitals to transitioning into obesity medicine, and her move to Cape Town.
In response to US funding cuts for South African health services and research projects, National Treasury has provided the National Department of Health with hundreds of millions of rands in emergency funds. Spotlight and GroundUp look at how precisely the government intends to spend this money.
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
South Africa’s National Department of Health is still to outline a clear contingency plan as a US funding freeze puts lives at risk, spells job losses, and presents threats to keeping HIV and TB under control. Ufrieda Ho reports.
A flexible silicone ring that slowly releases antiretrovirals is one of just two long-acting HIV prevention products registered for use in South Africa. Results from a new study might pave the way for a longer-acting version of the vaginal ring that provides three months of protection at a time, as opposed to one month with the current ring. Elri Voigt reports on these findings and looks at how the one-month ring has influenced HIV prevention choices in South Africa.
Most tuberculosis (TB) tests still require a trip to the clinic. Now, new technology has made it possible to test people at home. This could be a big deal for South Africa, where much TB goes undiagnosed. Tiyese Jeranji unpacks the findings and implications of a recent study into such TB home testing.
Inside Professor Linda-Gail Bekker’s office a bookshelf is stacked with titles on general medicine, HIV and tuberculosis. Against the bookshelf, a mannequin leans dressed in a white doctor’s coat, sparkling tiara and pink Venetian mask, with a stethoscope protruding from her pocket. Known to colleagues as LGB, Bekker is one of South Africa’s top HIV researchers. Biénne Huisman chatted to Bekker about her remarkable career, finding new ways to reach young people, her love of both art and science and the thinking behind the slogan “get ripped, get prepped”.
Last year Spotlight reported that pilot projects testing out a new HIV prevention injection and a vaginal ring in South Africa would start early in 2023. Yet, as delegates gathered for the SA AIDS Conference in Durban last week, those pilots hadn’t yet started. Alicestine October and Elri Voigt have the latest on the state of play with these critical projects.